- Molecular NameAcrivastine
- SynonymNA
- Weight348.446
- Drugbank_IDN/A
- ACS_NO87848-99-5
- Show 2D model
- LogP (experiment)2.83
- LogP (predicted, AB/LogP v2.0)3.38
- pkaN/A
- LogD (pH=7, predicted)0.88
- Solubility (experiment)Slightly soluble
- LogS (predicted, ACD/Labs)(ph=7)-3.98
- LogSw (predicted, AB/LogsW2.0)0.15
- Sw (mg/ml) (predicted, ACD/Labs)0.04
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds6
- TPSA53.43
- StatusFDA approved
- AdministrationN/A
- PharmacologyA medication used for the treatment of allergies and hay fever. It is a second-generation H1-receptor antagonist antihistamine and works by blocking H1 histamine receptors.
- Absorption_value88.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability18.0
- Protein binding50.0
- Volume of distribution (VD)0.64 L/kg (single dose); 0.75 L/kg (multiple)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe drug undergoes some metabolism to form a propionic acid analogue that has pharmacological activity and makes up approximately, 10% of the total plasma drug concentration.
- Half life1.4~2.1 h (acrivastine); 2.3 h (metabolite)
- ExcretionAbout 60% of an administered dose is excreted unchanged in urine and 15 to 17% of this is detected as the metabolite.
- Urinary ExcretionN/A
- CleranceTotal body, 4.41 ± 0.63 mL/min/kg
- ToxicityAdverse effects reported for Acrivastine/Pseudoephedrine combination are somnolence, headache, dizziness, nervousness, insomnia, nausea, dry mouth, asthenia, dyspepsia, pharyngitis, cough increase, dysmenorrhea.
- LD50 (rat)N/A
- LD50 (mouse)N/A